This trial is evaluating whether N-803 will improve 1 primary outcome and 1 secondary outcome in patients with HIV Infections. Measurement will happen over the course of 6 months.
This trial requires 10 total participants across 2 different treatment groups
This trial involves 2 different treatments. N-803 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Most HIV-positive men are not affected by any of the symptoms of AIDS. A small percentage of AIDS patients may develop fever, night sweats and weight loss.
The rate of new diagnoses among Americans varies, although a significant proportion of Americans have at least one infection. The number of new HIV infections per year ranged from 24,800 in San Francisco in 2012 to 31,700 in Miami in 2013. A few states, including Connecticut, Florida, Michigan, New York, and New Jersey, had the highest numbers of new HIV infections per year.
HIV is a chronic and progressive illness which cannot be cured. However, an effective combination antiretroviral regimen can reduce the incidence and severity of many of the acute and persistent symptoms of HIV infection such as fever and anemia, while minimizing the development of drug resistance.
A total of 30% of the adults in West Midlands had a personal history of a recent HIV infection. However it was not known what caused the infection. Some people thought it could be a result of having unsafe sex or an injection device. Others reported injecting needles and sharing clothing without washing thoroughly. Those who had an HIV infection thought that it was due to contracting it via blood transfusions. A full knowledge of HIV risk factors should be disseminated with accurate messages about prevention.
HIV infections is a chronic disease that usually takes many years to develop. The disease is often asymptomatic and many of those who are already diagnosed with the disease are unaware of their status. Symptoms may differ depending on the type of HIV infection. These symptoms include: fevers, weight loss, muscle pains and bleeding. HIV infections can also be transmitted through sexual activity, blood transfusion, shared drug needles or syringes during injection practices.
In this sample of women with hiv infections, few women wanted to remain uninfected, but most were treatment-seeking. A substantial percentage opted to not pursue treatment or engage in self-help instead.
There are ongoing research goals for the treatment of hiv/AIDS. The discovery of other new drugs that can target viral molecules could lead to a possible cure for hiv.
Data from a recent study of this study suggest that n-803 is generally well tolerated in subjects with advanced HIV, and with the potential for increased CD4+ T-cell counts, although safety has yet to be demonstrated.
In a recent study, findings supports the use of n-803 as a first-line treatment for HIV infection and the potential to help improve the quality of life.
In our study, the addition of n-803 to the HIV treatment did not change the immunologic response. Thus, even with the addition of n-803 to the antiretroviral therapy, CD4(+) T cells were not able to achieve sufficient levels to clear the infections. Nevertheless, the antiviral effects of n-803 were also not reversed by the treatment itself when compared to the non-infected control. The authors concluded that there is no evidence for the effects of n-803 in patients with HIV-1 infection who have already achieved high levels of viremia in the blood.
N808 was more effective than a placebo for patients with or without CD4 cell counts > or = 200 cells/mm; the efficacy of N808 in patients with CD4 cells>200/xl decreases significantly if the treatment is started earlier than two weeks after ART. N808 can be considered as a possible option in patients with severe immunodeficiencies.